Posts By Alex
-
403Wire Stories�Gigaphoton Expands Training Capability to Enhance Its Field Services
�Supporting increasing semiconductor lithography lightsources worldwide OYAMA, Japan–(BUSINESS WIRE)–Gigaphoton Inc. (Head Office: Oyama, Tochigi; President and CEO: Katsumi Uranaka), a manufacturer of...
-
485Wire StoriesJetour welcomed Javier Zanetti to the Carnival Night in Qatar
WUHU, China–(BUSINESS WIRE)–The final whistle blew, and Argentina won the title. Prior to it, the great Argentine football player Javier Zanetti performed...
-
528Wire StoriesJetour is Collaborating With Two Top 100 DJs to Light Up the Jetour Carnival Night!
WUHU, China–(BUSINESS WIRE)–With Qatar as its focal point, the football championship fever is sweeping the world. To celebrate the championship, Jetour, a...
-
488Wire StoriesNanahoshi Management Discloses Its Campaign Website �Optimize Yaizu (2812 JP Equity)�
Our first activist campaign website is now available TOKYO–(BUSINESS WIRE)–#2812JP–Nanahoshi Management, one of the activist investors in Japan and a shareholder of...
-
913Wire StoriesElpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-? Bispecific Antibody for Patients with Advanced Solid Tumors
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.–(BUSINESS WIRE)–Elpiscience Biopharmaceuticals, Inc. (�Elpiscience�), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit...
-
460Wire StoriesPeru Joins WTTC Guardians of Nature and Is Committed to Environmental Sustainability
LIMA, Peru–(BUSINESS WIRE)–Sustainability has become a vital element in development plans and programs in Peru and the Commission for the Promotion of...
-
375Wire StoriesBIO-key Secures $2.2M in Funding via Promissory Note Financing
WALL, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI) an innovative provider of Identity and Access Management (IAM)...
-
397Wire StoriesYescarta� Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
� Based on Landmark ZUMA-7 Study, Patients with LBCL Treated with Yescarta in Second-Line Achieved Four-Fold Greater Improvement in Event-Free Survival of...
-
467Wire StoriesEnfusion Names Oleg Movchan as Chief Executive Officer
NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-native SaaS solutions for investment managers,...
-
438Wire StoriesDOKODEMO Door VR Live Broadcasting Feature Released
TOKYO–(BUSINESS WIRE)–MATRIX Inc. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Junichi Goishi; hereinafter �MATRIX�) of the MetaReal Group is pleased to announce the release...
